Prognosis of bronchial artery embolization in the management of hemoptysis

Shin Ichi Osaki, Yoichi Nakanishi, Hiroshi Wataya, Koichi Takayama, Koji Inoue, Youichi Takaki, Sadayuki Murayama, Nobuyuki Hara

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Background: Bronchial artery embolization (BAE) is a well-accepted and widely used treatment modality for the management of massive and recurrent hemoptysis. However, few reports have previously investigated the long-term results. Objectives: To investigate the prognosis of patients with hemoptysis who had undergone BAE. Methods: Twenty-two patients with hemoptysis underwent BAE. The underlying diseases included bronchiectasis in 9, aspergillosis in 3, chronic bronchitis in 2, idiopathic bronchial bleeding in 4, and other diseases in 4. The follow-up period ranged from 25 to 88 months (median 47 months). Results: After the initial BAE, 11 of 22 (50%) patients had re- bleeding (5 patients with hemoptysis and 6 patients with minor hemosputa). Among them, 1 patient suffered from recurrent massive hemoptysis and died from airway obstruction within 1 month after BAE. In addition, 10 of these 11 (90.9%) patients experienced recurrent airway bleeding within 3 years after BAE. Recurrent cases of hemoptysis were seen in 6 of 22 patients (27.3%) within 3 years and no case recurred later than 3 years after BAE. A recurrence of hemoptysis was frequently seen in patients with either bronchiectasis or pulmonary-bronchial artery (P-B) shunt. Although BAE is an effective treatment for the immediate control of hemoptysis, 5 of the patients experienced recurrent bleeding in the long-term follow-up. Conclusions: It is important to follow-up such patients until 3 years after initial BAE, especially when either ectatic changes of the bronchi on a CT scan or a P-B shunt on angiographic findings are detected. Copyright (C) 2000 S. Karger AG, Basel.

Original languageEnglish
Pages (from-to)412-416
Number of pages5
JournalRespiration
Volume67
Issue number4
DOIs
Publication statusPublished - Jan 1 2000

Fingerprint

Bronchial Arteries
Hemoptysis
Hemorrhage
Bronchiectasis
Pulmonary Artery
Aspergillosis
Chronic Bronchitis
Airway Obstruction
Bronchi

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine

Cite this

Osaki, S. I., Nakanishi, Y., Wataya, H., Takayama, K., Inoue, K., Takaki, Y., ... Hara, N. (2000). Prognosis of bronchial artery embolization in the management of hemoptysis. Respiration, 67(4), 412-416. https://doi.org/10.1159/000029540

Prognosis of bronchial artery embolization in the management of hemoptysis. / Osaki, Shin Ichi; Nakanishi, Yoichi; Wataya, Hiroshi; Takayama, Koichi; Inoue, Koji; Takaki, Youichi; Murayama, Sadayuki; Hara, Nobuyuki.

In: Respiration, Vol. 67, No. 4, 01.01.2000, p. 412-416.

Research output: Contribution to journalArticle

Osaki, SI, Nakanishi, Y, Wataya, H, Takayama, K, Inoue, K, Takaki, Y, Murayama, S & Hara, N 2000, 'Prognosis of bronchial artery embolization in the management of hemoptysis', Respiration, vol. 67, no. 4, pp. 412-416. https://doi.org/10.1159/000029540
Osaki SI, Nakanishi Y, Wataya H, Takayama K, Inoue K, Takaki Y et al. Prognosis of bronchial artery embolization in the management of hemoptysis. Respiration. 2000 Jan 1;67(4):412-416. https://doi.org/10.1159/000029540
Osaki, Shin Ichi ; Nakanishi, Yoichi ; Wataya, Hiroshi ; Takayama, Koichi ; Inoue, Koji ; Takaki, Youichi ; Murayama, Sadayuki ; Hara, Nobuyuki. / Prognosis of bronchial artery embolization in the management of hemoptysis. In: Respiration. 2000 ; Vol. 67, No. 4. pp. 412-416.
@article{a9c077c68c714b5fb692ece991fbad81,
title = "Prognosis of bronchial artery embolization in the management of hemoptysis",
abstract = "Background: Bronchial artery embolization (BAE) is a well-accepted and widely used treatment modality for the management of massive and recurrent hemoptysis. However, few reports have previously investigated the long-term results. Objectives: To investigate the prognosis of patients with hemoptysis who had undergone BAE. Methods: Twenty-two patients with hemoptysis underwent BAE. The underlying diseases included bronchiectasis in 9, aspergillosis in 3, chronic bronchitis in 2, idiopathic bronchial bleeding in 4, and other diseases in 4. The follow-up period ranged from 25 to 88 months (median 47 months). Results: After the initial BAE, 11 of 22 (50{\%}) patients had re- bleeding (5 patients with hemoptysis and 6 patients with minor hemosputa). Among them, 1 patient suffered from recurrent massive hemoptysis and died from airway obstruction within 1 month after BAE. In addition, 10 of these 11 (90.9{\%}) patients experienced recurrent airway bleeding within 3 years after BAE. Recurrent cases of hemoptysis were seen in 6 of 22 patients (27.3{\%}) within 3 years and no case recurred later than 3 years after BAE. A recurrence of hemoptysis was frequently seen in patients with either bronchiectasis or pulmonary-bronchial artery (P-B) shunt. Although BAE is an effective treatment for the immediate control of hemoptysis, 5 of the patients experienced recurrent bleeding in the long-term follow-up. Conclusions: It is important to follow-up such patients until 3 years after initial BAE, especially when either ectatic changes of the bronchi on a CT scan or a P-B shunt on angiographic findings are detected. Copyright (C) 2000 S. Karger AG, Basel.",
author = "Osaki, {Shin Ichi} and Yoichi Nakanishi and Hiroshi Wataya and Koichi Takayama and Koji Inoue and Youichi Takaki and Sadayuki Murayama and Nobuyuki Hara",
year = "2000",
month = "1",
day = "1",
doi = "10.1159/000029540",
language = "English",
volume = "67",
pages = "412--416",
journal = "Respiration; international review of thoracic diseases",
issn = "0025-7931",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - Prognosis of bronchial artery embolization in the management of hemoptysis

AU - Osaki, Shin Ichi

AU - Nakanishi, Yoichi

AU - Wataya, Hiroshi

AU - Takayama, Koichi

AU - Inoue, Koji

AU - Takaki, Youichi

AU - Murayama, Sadayuki

AU - Hara, Nobuyuki

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Background: Bronchial artery embolization (BAE) is a well-accepted and widely used treatment modality for the management of massive and recurrent hemoptysis. However, few reports have previously investigated the long-term results. Objectives: To investigate the prognosis of patients with hemoptysis who had undergone BAE. Methods: Twenty-two patients with hemoptysis underwent BAE. The underlying diseases included bronchiectasis in 9, aspergillosis in 3, chronic bronchitis in 2, idiopathic bronchial bleeding in 4, and other diseases in 4. The follow-up period ranged from 25 to 88 months (median 47 months). Results: After the initial BAE, 11 of 22 (50%) patients had re- bleeding (5 patients with hemoptysis and 6 patients with minor hemosputa). Among them, 1 patient suffered from recurrent massive hemoptysis and died from airway obstruction within 1 month after BAE. In addition, 10 of these 11 (90.9%) patients experienced recurrent airway bleeding within 3 years after BAE. Recurrent cases of hemoptysis were seen in 6 of 22 patients (27.3%) within 3 years and no case recurred later than 3 years after BAE. A recurrence of hemoptysis was frequently seen in patients with either bronchiectasis or pulmonary-bronchial artery (P-B) shunt. Although BAE is an effective treatment for the immediate control of hemoptysis, 5 of the patients experienced recurrent bleeding in the long-term follow-up. Conclusions: It is important to follow-up such patients until 3 years after initial BAE, especially when either ectatic changes of the bronchi on a CT scan or a P-B shunt on angiographic findings are detected. Copyright (C) 2000 S. Karger AG, Basel.

AB - Background: Bronchial artery embolization (BAE) is a well-accepted and widely used treatment modality for the management of massive and recurrent hemoptysis. However, few reports have previously investigated the long-term results. Objectives: To investigate the prognosis of patients with hemoptysis who had undergone BAE. Methods: Twenty-two patients with hemoptysis underwent BAE. The underlying diseases included bronchiectasis in 9, aspergillosis in 3, chronic bronchitis in 2, idiopathic bronchial bleeding in 4, and other diseases in 4. The follow-up period ranged from 25 to 88 months (median 47 months). Results: After the initial BAE, 11 of 22 (50%) patients had re- bleeding (5 patients with hemoptysis and 6 patients with minor hemosputa). Among them, 1 patient suffered from recurrent massive hemoptysis and died from airway obstruction within 1 month after BAE. In addition, 10 of these 11 (90.9%) patients experienced recurrent airway bleeding within 3 years after BAE. Recurrent cases of hemoptysis were seen in 6 of 22 patients (27.3%) within 3 years and no case recurred later than 3 years after BAE. A recurrence of hemoptysis was frequently seen in patients with either bronchiectasis or pulmonary-bronchial artery (P-B) shunt. Although BAE is an effective treatment for the immediate control of hemoptysis, 5 of the patients experienced recurrent bleeding in the long-term follow-up. Conclusions: It is important to follow-up such patients until 3 years after initial BAE, especially when either ectatic changes of the bronchi on a CT scan or a P-B shunt on angiographic findings are detected. Copyright (C) 2000 S. Karger AG, Basel.

UR - http://www.scopus.com/inward/record.url?scp=0033839688&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033839688&partnerID=8YFLogxK

U2 - 10.1159/000029540

DO - 10.1159/000029540

M3 - Article

C2 - 10940796

AN - SCOPUS:0033839688

VL - 67

SP - 412

EP - 416

JO - Respiration; international review of thoracic diseases

JF - Respiration; international review of thoracic diseases

SN - 0025-7931

IS - 4

ER -